AGLS
Sponsors
Ahn-Gook Pharmaceuticals Co.,Ltd
Conditions
Essential HypertensionHypertension
Phase 3
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension
NCT04686643
Start: 2021-02-01End: 2022-05-01Target: 306Updated: 2020-12-29
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
CompletedNCT05503953
Start: 2022-09-13End: 2025-06-10Updated: 2026-09-10